Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes

Thalange N, Deeb L, Iotova V, Kawamura T, Klingensmith G, Philotheou A, Silverstein J, Tumini S, Ocampo Francisco A-M, Kinduryte O, Danne T.

Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes.

Pediatric Diabetes 2015: 16: 164–176.

Insulin degludec (IDeg) once-daily was compared with insulin detemir (IDet) once- or twice-daily, with prandial insulin aspart in a treat-to-target, randomized controlled trial in children 1–17 yr with type 1 diabetes, for 26 wk (n = 350), followed by a 26-wk extension (n = 280). Participants were randomized to receive either IDeg once daily at the same time each day or IDet given once or twice daily according to local labeling. Aspart was titrated according to a sliding scale or in accordance with an insulin:carbohydrate ratio and a plasma glucose correction factor. Randomization was age-stratified: 85 subjects 1–5 yr. (IDeg: 43), 138 6–11 yr (IDeg: 70) and 127 12–17 yr (IDeg: 61) were included. Baseline characteristics were generally similar between groups overall and within each stratification. Non-inferiority of IDeg vs. IDet was confirmed for HbA1c at 26 wk; estimated treatment difference (ETD) 0.15% [-0.03; 0.32]%95%CI. At 52 wk, HbA1c was 7.9% (IDeg) vs. 7.8% (IDet), NS; change in mean FPG was −1.29 mmol/L (IDeg) vs. +1.10 mmol/L (IDet) (ETD −1.62 mmol/L [-2.84; −0.41]%95%CI, p = 0.0090) and mean basal insulin dose was 0.38 U/kg (IDeg) vs. 0.55 U/kg (IDet). The majority of IDet treated patients (64%) required twice-daily administration to achieve glycemic targets. Hypoglycemia rates did not differ significantly between IDeg and IDet, but confirmed and severe hypoglycemia rates were numerically higher with IDeg (57.7 vs. 54.1 patient-years of exposure (PYE) [NS] and 0.51 vs. 0.33, PYE [NS], respectively) although nocturnal hypoglycemia rates were numerically lower (6.0 vs. 7.6 PYE, NS). Rates of hyperglycemia with ketosis were significantly lower for IDeg vs. IDet (0.7 vs. 1.1 PYE, treatment ratio 0.41 (0.22; 0.78)%95%CI, p = 0.0066). Both treatments were well tolerated with comparable rates of adverse events. IDeg achieved equivalent long-term glycemic control, as measured by HbA1c with a significant FPG reduction at a 30% lower basal insulin dose when compared with IDet. Rates of hypoglycemia did not differ significantly between the two treatment groups; however, hyperglycemia with ketosis was significantly reduced in those treated with IDeg.
Introduction

The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study showed conclusively that good glycemic control delays, and may even prevent, the development of long-term complications in type 1 diabetes (T1D) (1–5). Management of T1D in children and adolescents presents particular challenges. Factors that increase the complexity of treating children include hormonal changes during normal growth and development (e.g., rapid growth, pubertal insulin resistance, psychosocial and cognitive development), family dynamics (including socioeconomic status, cultural considerations and parent/caregiver viewpoints) and the provision and quality of care and support outside the home, for example at school/college (6). In recognition of this, the American Diabetes Association and the International Society for Pediatric and Adolescent Diabetes (ISPAD) have published specific guidance for children (7, 8).

Hypoglycemia is one of the main side effects of insulin therapy and is often viewed as the major barrier to achieving good glycemic control by parents and physicians alike. A number of studies have shown that hypoglycemia has a detrimental effect on the cognitive development of young children, and that episodes of hypoglycemia, particularly nocturnal hypoglycemia, can be extremely frightening both for children and their parents/caregivers (9, 10). It can therefore be tempting to set higher glycemic targets to minimize hypoglycemia. In addition, fear of hypoglycemia can lead to reluctance to titrate to appropriate glucose targets, with resultant hyperglycemia and suboptimal HbA1c. However, undertreatment can place children at-risk of hyperglycemia with ketosis, which, if left untreated, can progress to diabetic ketoacidosis (DKA) (11). The risk of DKA in children with established T1D is up to 10% per patient per year (11). Children who restrict or omit insulin intentionally, or unintentionally due to unstable family circumstances or limited access to supplies, are at greatly increased risk (12, 13). Basal insulin can help reduce the risk of DKA by providing a continual background level of insulin. The long-acting analogs insulin glargine (IGlar) and insulin detemir (IDet) can provide up to 24-h coverage when administered once daily (OD) or twice-daily (BID) in the case of IDet (14, 15). However, because of their action profile, administration should ideally be at the same time each day to prevent periods of insulin insufficiency (14, 15). As children of all ages often have highly variable daily schedules, a basal regimen that provides flexibility in dosing time may be beneficial.

Insulin degludec (IDeg), a new basal insulin for the treatment of T1D and type 2 diabetes (T2D), has been showed to have an ultra-long duration of action and low variability in adults, producing a consistent glucose-lowering activity profile at steady state (16, 17). Pharmacokinetic data have shown that IDeg has a terminal half-life of approximately 25 h, twice that of IGlar, and a duration of action of more than 42 h (18). A phase 3, randomized, controlled trial in adults with T1D confirmed that IDeg OD effectively reduced HbA1c and fasting plasma glucose (FPG), with a lower risk of nocturnal confirmed hypoglycemia than IGlar (19). Furthermore, studies in adults with T1D and T2D have shown that the IDeg injection time may be varied from day to day without compromising efficacy or safety, offering patients greater convenience and flexibility, when needed (20, 21).

The objective of this trial was to investigate the efficacy and safety of IDeg vs. IDet, both in combination with bolus insulin aspart (IAsp), in children and adolescents with T1D (Fig. 1).

Materials and methods

Trial conduct

This was a 26-wk, phase 3b, randomized, controlled, open-label, multinational, parallel-group, treat-to-target non-inferiority trial with a 26-wk extension, comparing the efficacy and safety of IDeg administered OD with that of IDet administered OD or BID, both in combination with mealtime IAsp. The study was conducted at 72 sites in 12 countries (Bulgaria, Finland, France, Germany, Italy, Japan, the Netherlands, Republic of Macedonia, Russian Federation, South Africa, UK and USA). Of these, South Africa did not participate in the 26-wk extension phase as regulatory approval was not granted. The protocol, protocol amendments, consent form, child assent form, subject information sheet and other information provided to the participants and parents/participants’ legal representatives were approved by the relevant independent ethics committees or institutional review boards (written informed consent was obtained prior to participant enrolment) and the trial was conducted according to the Declaration of Helsinki (22) and ICH Good Clinical Practice (23). In some countries assent from children themselves (≤17 yr of age, where appropriate) was required in addition to parental consent. Ongoing safety surveillance was performed by a blinded internal Novo Nordisk safety committee and an unblinded independent Data Monitoring Committee (comprising pediatric and endocrine experts). This trial is registered at www.clinicaltrials.gov: NCT01513473.

Children and adolescents (1–17 yr of age) with T1D who had been receiving insulin treatment (any regimen) for at least 3 months, without concomitant oral antidiabetic drugs and with HbA1c levels of ≤11%, were eligible for inclusion (Fig. S1, Supporting Information).
363 participants assessed for eligibility

350 enrolled and randomized 1:1

174 allocated to IDeg and exposed

176 allocated to IDet

13 participants excluded

170 completed main trial (97.7%)

165 completed main trial (93.7%)

175 exposed to treatment

11 withdrawn (6.3%)

2 adverse events (1.1%)

0 non-compliance (0%)

0 ineffective therapy (0%)

7 withdrawal criteria (4.0%)

2 other (1.1%)

1 withdrew prior to treatment

162 entered extension and exposed (87.4%)

128 entered extension and exposed (72.7%)

1 withdrawn prior to treatment

6 withdrawn (3.4%)

1 adverse event (0.6%)

0 non-compliance (0%)

0 ineffective therapy (0%)

5 withdrawal criteria (2.8%)

0 other (0%)

151 completed extension (86.8%)

122 completed extension (69.3%)

Fig. 1. Participant disposition. IDeg, insulin degludec; IDet, insulin detemir.

Randomization

Following screening, eligible participants were randomized 1:1, using a central interactive voice/web response system, to receive either IDeg (100 U/mL, Penfill® 3-mL cartridge, Novo Nordisk, Bagsværd, Denmark) or IDet (100 U/mL, Penfill® 3-mL cartridge; Novo Nordisk). Randomization was also stratified by age group: 1–5, 6–11 and 12–17 yr, to ensure an approximately equal distribution of participants between treatment arms within each age group.

Procedures

To ensure treatment uniformity between clinics, and to ensure that the patients received optimal treatment, insulin treatment algorithms were developed specifying recommended dose adjustments at different PG levels. Clinical judgment had to be applied to avoid increased risks for the patients. Thus the investigators could overrule the guidelines when necessary. Eligible participants were switched to either IDeg OD or IDet OD or BID with mealtime IAsp at randomization (wk 0). Participants switching to IDet received their dose OD or BID in accordance with local labeling. Participants switching to IDeg received a single dose at the same time each day. The total daily insulin dose was calculated and used to derive the trial bolus and basal doses using the initiation table provided (Table S1), aiming for a basal:bolus ratio of between 50:50 and 30:70 with no basal dose reduction, as this range was generally considered to be appropriate for children with T1D. For example, if the participant’s total daily insulin dose prior to the trial was 28 U, the participant would receive a total of 8 U of IDeg or IDet and 20 U of insulin aspart at the ratio of 30:70. The choice of basal:bolus split for each individual was made at the discretion of the investigator. At 26 wk, for those participants not continuing in the extension study, basal insulin was switched to neutral protamine Hagedorn insulin for 7 days to minimize interference with antibody detection at a follow-up visit performed 1 wk later. For those entering the extension study, this was done at 52 wk.

The overall trial duration was approximately 53 wk, including two 26-wk treatment periods and one 7-day basal insulin washout period (Fig. S1). A treat-to-target approach was used to optimize glycemic control and
achieve a pre-breakfast self-measured plasma glucose (SMPG) target of 5–8 mmol/L, in accordance with ISPAD guidelines (7). IDeg OD and IDet OD titration was based on the lowest pre-breakfast SMPG value, using glucose meters calibrated to plasma values, on the 3 days prior to each weekly visit(phone contact, and adjusted using a standard titration algorithm (Table 1). Participants receiving IDet OD whose mean pre-breakfast SMPG had reached target but whose mean pre-dinner plasma glucose (PG) was >8.0 mmol/L (145 mg/dL) commenced an additional morning dose of IDet at 2–4 U, with a pre-dinner titration target of 5–8 mmol/L. If using IDet BID, morning dose titration was based on the lowest pre-dinner SMPG and evening dose titration on the lowest pre-breakfast SMPG on the 3 days prior to each visit(phone contact. Titration of IAsp was performed either by use of PG correction factors and insulin:carbohydrate ratios or once weekly, based on the lowest of three SMPG values measured 3 days before a visit(phone contact; pre-meal doses were adjusted according to the lowest post-meal increment observed over the preceding 3 days (Table 1). Carbohydrate counting was only used by those participants and caregivers that had prior experience with this method.

The primary endpoint was change from baseline in HbA1c after 26 wk of treatment. Other efficacy endpoints assessed at both wk 26 and wk 52 included FPG, analyzed by central laboratory, and 4- and 8-point SMPG profiles. Self-measured glucose measurements were performed with capillary blood automatically calibrated to plasma-equivalent glucose values, using a glucose monitor able to capture both blood glucose and blood ketones, which was centrally supplied. Four-point profiles were performed weekly and 8-point profiles were performed at wk 0 (randomization), 12, 26, 38 and 52. Safety variables included adverse events (AEs), hypoglycemic episodes, hyperglycemia, incidence of hyperglycemia with elevated ketones (>1.5 mmol/L), insulin dose, body weight, antibodies and standard laboratory safety assessments. Confirmed hypoglycemia was defined as SMPG <3.1 mmol/L (56 mg/dL) and/or severe episodes as defined by ISPAD [the child has altered mental status and cannot assist in their own care, is semiconscious or unconscious, or in a coma ± convulsions and may require parenteral therapy (glucagon or i.v. glucose)]. The ISPAD definition is very broad and includes a subjective element: ‘The child has altered mental status and cannot assist in his own care’, and determining whether an episode fulfills the definition can be challenging, especially in young children. Therefore, all reported episodes of severe hypoglycemia were reviewed in a blinded manner by an independent, external pediatric endocrinologist, in order to determine whether the episodes fulfilled the criteria for severe hypoglycemia. Hypoglycemic episodes occurring between 11 pm and 7 am inclusive were classified as nocturnal.

Hyperglycemia was defined as PG values >11.1 mmol/L (200 mg/dL). Hyperglycemia with ketosis was defined when PG exceeded 14.0 mmol/L (252 mg/dL) and the capillary blood ketones exceeded 1.5 mmol/L (27 mg/dL).

Laboratory analyses were conducted at central laboratories (Quintiles Laboratories Europe, Livingston, UK; Quintiles Laboratories South Africa, Centurion, South Africa; Quintiles Laboratories Limited, Marietta, Georgia; Quintiles Laboratories Japan, Tokyo, Japan), with the exception of FPG, which was analyzed at Laboratorium für Klinische Forschung GmbH (Schwентintal, Germany). Antibody analyses were conducted at Celerion Switzerland AG (Fehraltorf, Switzerland), using a validated radioimmunoassay method (24, 25).

Table 1. Insulin titration algorithms

| Current basal dose | ≤5 U | 5–15 U | >15 U |
|--------------------|------|--------|-------|
| Pre-breakfast or pre-dinner plasma glucose | U | U |
| mmol/L | mg/dL | U |
| <5.0 | <90 | −1/2 | −1 |
| 5.0–8.0 | 90–145 | 0 | 0 |
| 8.1–10.0 | 146–180 | +1/2 | +1 |
| 10.1–15.0 | 181–270 | +1 | +2 |
| >15.0 | >270 | +1 | +3 |

| Current bolus dose | ≤5U | >5U |
|--------------------|-----|-----|
| Lowest pre-meal or bedtime plasma glucose | U | U |
| mmol/L | mg/dL | U |
| <5.0 | <90 | −1/2 | −1 |
| 5.0–8.0 | 90–145 | 0 | 0 |
| 8.1–10.0 | 146–180 | +1/2 | +1 |
| 10.1–15.0 | 181–270 | +1 | +2 |
| >15.0 | >270 | +1 | +3 |

Continuous glucose monitoring

Continuous glucose monitoring (CGM) was conducted in a subset of participants in the IDeg group (74 participants) and IDet group (75 participants) at selected sites in Bulgaria, Finland, France, Germany, Italy, the Netherlands, UK, South Africa, Russia and US during the main trial period only. Interstitial glucose (IG) profiles obtained by CGM were performed over a period of 3–6 continuous days. The CGM system (MedTronic International, Switzerland) recorded IG values every fifth minute. CGM was measured between screening and randomization, and again after at least 5 months of treatment.

Statistical methods

The primary objective was to confirm the non-inferiority of IDeg OD to IDet, both with mealtime
IAsp, in controlling glycaemia with respect to change from baseline in HbA1c after 26 wk of treatment. Non-inferiority was confirmed if the upper limit of the two-sided confidence interval (CI) for the treatment difference for mean change in HbA1c was ≤0.4%, in accordance with regulatory guidelines (26). The sample size was determined using a \( t \)-statistic under the assumption of a one-sided test of size 2.5%, a zero mean treatment difference and standard deviation (SD) of 1.25% for HbA1c. A total of 346 participants had to be randomized to achieve at least 80% or greater power in the evaluation of the per protocol (PP) analysis set, after adjustment for a 10% dropout rate.

Statistical analyses of all efficacy and safety endpoints included all randomized participants [full analysis set (FAS)], following the intention-to-treat principle. No statistical analyses were performed at the stratified age-group data level as the numbers were too low. Descriptive tables and figures were based on FAS for efficacy endpoints and on the safety analysis set (SAS), consisting of all randomized participants exposed to at least one dose of the investigational product, for safety endpoints. Missing values were imputed using last observation carried forward. Comparisons between IDeg and IDet were analyzed at 26 and 52 wk.

Baseline characteristics, demographics, AEs and number of hypoglycemic episodes (including CGM measurements) are presented using descriptive statistics. Treatment differences in change in HbA1c, FPG, body weight and duration of low/high IG measurements by CGM were estimated using analysis of variance (ANOVA), adjusted by treatment, sex, region, age group and baseline value of the respective endpoint. The robustness of the analysis of change in HbA1c from baseline to wk 26 was explored by additional analyses, including analysis of the PP set. Hypoglycemic events and number of low/high IG readings according to CGM were modeled using negative binomial regression, adjusted by treatment, sex, region and age group as fixed factors and with the logarithm of the time period for which a hypoglycemic episode is considered treatment emergent as offset. This time period was defined as the time elapsed from the first day of treatment with investigational product to 7 days after was defined as the time elapsed from the first day of treatment. The observed mean decrease in HbA1c was slightly higher in the IDeg arm; Table 2. The pre-trial regimen of most participants (95.7%) comprised basal–bolus therapy. Of those on alternative regimens, 4% were using premix insulin (alone or combined with either basal or bolus insulin), 0.3% were using basal insulin alone and 1.4% were using bolus insulin alone.

Glycemic control

Non-inferiority of IDeg to IDet with respect to change in HbA1c from baseline to wk 26 was confirmed [estimated treatment difference (ETD) IDeg–IDet: 0.15%-points, (0.03; 0.32), 95% CI (1.6 mmol/mol, (0.3; 3.5)95% CI)]. The robustness of the primary analysis was supported by analysis of the PP set [ETD IDeg–IDet: 0.19%-points, (0.01; 0.37), 95% CI (2.0 mmol/mol, (0.1; 4.0)95% CI)] and other sensitivity analyses (data not shown). The observed mean decrease in HbA1c from baseline to wk 52 was similar between IDeg [−0.27%-points (3 mmol/mol)] and IDet [−0.22%-points (2.4 mmol/mol)] groups and the trend over time in HbA1c was also similar (Fig. 2A). Similar between-treatment reductions in HbA1c were also observed in children 1–5yr of age [−0.36%-points (3.9 mmol/mol) for IDeg1–5 and −0.16%-points (1.7 mmol/mol) for IDet1–5], children 6–11yr of age [−0.35%-points (3.8 mmol/mol) for IDeg6–11, −0.33%-points (3.6 mmol/mol) for IDet6–11] and adolescents 11–17yr of age [−0.10%-points (1.1 mmol/mol) for IDeg11–17 and −0.14%-points (1.5 mmol/mol) for IDet11–17], respectively, at 52 wk.

Results

Patient characteristics

Of the 350 randomized participants, 349 (99.7%) were exposed and most [170/174 (97.7%) for IDeg, 165/175 (93.7%) for IDet] completed the main trial period. The percentage of participants withdrawn during the main period from the IDet group was higher than from the IDeg group (6.3 vs. 2.3%, respectively; see Fig. 1. The majority of withdrawals were because of participants meeting pre-specified withdrawal criteria including withdrawal of consent (Table S2). Of 170 main trial completers in the IDeg group, 152 (87.4%) continued into the extension and 151 (86.8%) of those randomized in the main trial completed the extension period. In contrast, of 165 main trial completers in the IDet group, only 128 (72.7% of participants randomized to IDet) continued into the extension and 122 (69.3% of participants randomized to IDet) completed the extension period (Fig. 1). Baseline characteristics overall and in the stratified age groups were representative for a pediatric population with T1D and both groups were well matched at baseline, with the exception of HbA1c and FPG which were slightly higher in the IDeg arm; Table 2. The pre-trial regimen of most participants (95.7%) comprised basal–bolus therapy. Of those on alternative regimens, 4% were using premix insulin (alone or combined with either basal or bolus insulin), 0.3% were using basal insulin alone and 1.4% were using bolus insulin alone.
Table 2. Participant baseline characteristics

| Characteristic                              | IDeg      | IDet      |
|---------------------------------------------|-----------|-----------|
| Full analysis set (FAS), n                  | 174       | 176       |
| 1–5                                         | 43        | 42        |
| 6–11                                        | 70        | 68        |
| 12–17                                       | 61        | 66        |
| Female/Male (%)                             | 44.8/55.2 | 44.3/55.7 |
| 1–5                                         | 46.5/53.5 | 59.5/40.5 |
| 6–11                                        | 42.9/57.1 | 39.7/60.3 |
| 12–17                                       | 45.9/54.1 | 39.4/60.6 |
| Race: White/Black/Asian/Other (%)           | 78.2/2.9/13.2/5.7 | 71.0/2.8/18.2/8.0 |
| 1–5                                         | 86.0/2.3/2/3/9.3 | 78.6/2.4/9.5/9.5 |
| 6–11                                        | 77.1/1.4/14.3/7.2 | 72.1/1.5/17.6/8.8 |
| 12–17                                       | 73.8/4.9/19.7/1.6 | 65.2/4.5/24.2/6.0 |
| Ethnicity: Hispanic or Latin American (%)   | 4.0       | 1.7       |
| 1–5                                         | 9.3       | 2.4       |
| 6–11                                        | 4.3       | 2.9       |
| 12–17                                       | 0         | 0         |
| Age (yr)                                    | 10.0 (±4.4) | 10.0 (±4.4) |
| 1–5                                         | 4.3 (±1.1) | 4.1 (±1.1) |
| 6–11                                        | 9.3 (±1.7) | 9.2 (±1.7) |
| 12–17                                       | 14.8 (±1.7) | 14.6 (±1.8) |
| Weight (kg)                                 | 38.0 (±18.7) | 37.8 (±18.9) |
| 1–5                                         | 18.0 (±4.0) | 17.8 (±3.8) |
| 6–11                                        | 32.9 (±7.7) | 31.4 (±8.1) |
| 12–17                                       | 57.9 (±14.5) | 57.2 (±14.2) |
| BMI (kg/m²)                                 | 18.7 (±3.6) | 18.5 (±3.6) |
| 1–5                                         | 16.2 (±1.7) | 16.3 (±1.7) |
| 6–11                                        | 17.7 (±2.6) | 17.1 (±2.3) |
| 12–17                                       | 21.6 (±3.8) | 21.5 (±3.6) |
| Duration of diabetes (yr)                  | 3.9 (±3.6) | 4.0 (±3.4) |
| 1–5                                         | 1.4 (±1.0) | 1.4 (±1.0) |
| 6–11                                        | 3.2 (±2.4) | 3.9 (±2.4) |
| 12–17                                       | 6.4 (±4.3) | 5.7 (±4.2) |
| HbA1c (%)                                   | 8.2 (±1.1) | 8.0 (±1.1) |
| 1–5                                         | 8.1 (±1.2) | 8.0 (±1.3) |
| 6–11                                        | 8.1 (±1.0) | 8.1 (±1.0) |
| 12–17                                       | 8.3 (±1.1) | 8.0 (±1.1) |
| HbA1c (mmol/mol*)                           | 66.1      | 63.9      |
| 1–5                                         | 65.0      | 63.9      |
| 6–11                                        | 65.0      | 65.0      |
| 12–17                                       | 67.2      | 63.9      |
| FPG, mmol/L [mg/dL]                         | 9.0 (±5.2) [162.1 (±94.4)] | 8.4 (±4.9) [151.0 (±87.7)] |
| 1–5                                         | 9.3 (±6.0) [167.5 (±107.6)] | 9.2 (±5.2) [166.0 (±93.5)] |
| 6–11                                        | 9.3 (±4.1) [166.8 (±74.3)] | 8.2 (±3.0) [147.6 (±89.4)] |
| 12–17                                       | 8.5 (±5.8) [163.6 (±105.1)] | 8.1 (±4.6) [146.1 (±82.5)] |

*Calculated value.
Data are mean (SD) unless otherwise stated.

At 52 wk, there was a statistically significant difference in laboratory-analyzed FPG, which decreased from baseline in the IDeg group, but increased in the IDet group. With IDeg, the mean FPG decreased from 9.0 to 7.8 mmol/L, corresponding to a change of −1.29 mmol/L. With IDet the mean FPG increased from 8.4 to 9.5 mmol/L, corresponding to a change of +1.10 mmol/L. ETD (IDeg–IDet): −1.67 mmol/L [−2.24; −0.01]95%CI, p = 0.0090, Fig. 2B. Similar patterns were observed for the three age groups and for the ETS population, both overall (−1.67 mmol/L in the IDeg group and +0.48 mmol/L in the IDet group) and stratified by age group.

After 52 wk, the change from baseline in the mean of the 8-point SMPG profiles was significantly different for the two treatments. The observed mean change was −0.7 mmol/L with IDeg and +0.3 mmol/L with IDet, ETD (IDeg–IDet): −0.79 mmol/L (−1.32; −0.26)95%CI, p = 0.0036 (Fig. 1C). Similar patterns were observed between age groups. In the IDeg group, post-prandial SMPG values at wk 12, 26, 38 and 52 decreased from baseline, whilst there was no apparent reduction in the IDet group. After 52 wk, there was a statistically significant treatment difference post-breakfast [IDeg–IDet: −1.57 mmol/L (−2.65; −0.49)95%CI, p = 0.0045], post-dinner [IDeg–IDet:
Fig. 2. Mean HbA\(_1c\) over time (panel A) mean FPG over time (panel B) and mean 8-point SMPG profiles at wk 0 and wk 56 (panel C). Mean values with error bars (standard error of the mean) based on full analysis set and last observation carried forward imputed data. P-values are from an ANCOVA model. IDeg, insulin degludec; IDet, insulin detemir, SMPG, self-measured plasma glucose.

At baseline, the mean daily basal dose was slightly lower in the IDeg group compared with the IDet group (0.37 vs. 0.40 units/kg, respectively) and remained fairly constant throughout the trial, reaching 0.38 U/kg by wk 52. By contrast, the mean daily basal dose in the IDet group increased over the study duration (Fig. 3). The mean daily dose of IDeg remained lower than that of IDet throughout the trial and across the three age groups (Table 3). The overall pattern was similar in the ETS, apart from a slightly lower basal insulin dose at wk 1 in participants 6–11 yr of age in the IDet group compared with the SAS (0.39 vs. 0.42 U/kg). After 52 wk, 112 (64%) participants were using IDet BID. Mean daily IAsp dose increased gradually during the trial in both treatment groups. After 52 wk, mean daily IAsp dose was marginally lower in the IDeg group compared with the IDet group (0.55 vs. 0.58 U/kg) (Table 3). After 52 wk of treatment, participants receiving IDeg required 30% less basal insulin, and 18% less insulin overall, and the basal:bolus ratios were 1.04, (0.93; 1.16) 95%CI. Within-subject variability in pre-breakfast SMPG after 52 wk was similar for the two treatment arms; ETD (IDeg-IDet): 1.04, (0.93; 1.16) 95%CI.

Table 3. Mean insulin doses

| Mean insulin dose | IDeg | IDet |
|-------------------|------|------|
| Number of patients (n) | 174 | 175 |
| Basal, U/kg (U) | 0.37 (15) | 0.40 (16) |
| End of trial | 0.38 (17) | 0.55 (24) |
| Bolus, U/kg (U) | 0.50 (20) | 0.52 (20) |
| End of trial | 0.55 (24) | 0.58 (24) |
| Total, U/kg (U) | 0.87 (35) | 0.93 (36) |
| End of trial | 0.93 (41) | 1.13 (48) |

IDeg, Insulin degludec; IDet, insulin detemir.
Hypoglycemia

At 52 wk, rates of confirmed hypoglycemia [i.e., PG < 3.1 mmol/L and/or severe (altered mental status, cannot assist in own care, semiconscious/unconscious, or in coma ± convulsions)] were similar for IDEg and IDEt [57.7 vs. 54.1 events/exposure year, estimated rate ratio (ERR): 1.11 (0.89; 1.38) 95% CI, NS] (Fig. 4A and Table 4), as were rates of nocturnal hypoglycemia [6.0 vs. 7.6 events/exposure year, ERR 0.99 (0.72; 1.34) 95% CI, NS; Fig. 4B and Table 4]. Incidence and rates of severe hypoglycemia were numerically higher with IDEg than IDEt, but the difference was not statistically significant: 17.8 vs. 13.7%; 0.51 vs. 0.33 events/exposure year [ERR 1.30 (0.64; 2.64) 95% CI, NS; Table 4]. Rates of severe hypoglycemia, including only episodes of semi consciousness/unconsciousness and coma ± convulsions, were 0.09 and 0.14 events/exposure year for IDEg and IDEt, respectively [ERR 0.62 (0.24; 1.60) 95% CI, NS; post hoc analysis based on external classification of severe hypoglycemic episodes; Table 4].

Participants in the IDEt group continuing in the extension had markedly lower rates of both confirmed (0.31 vs. 0.63 events/exposure year) and severe (50 vs. 80 events/exposure year), but not nocturnal confirmed (7.3 vs. 6.9 events/exposure year) hypoglycemia at 26 wk compared with those discontinuing after the main trial period. In the IDEg arm, those continuing into the extension had higher rates of severe hypoglycemia (0.48 vs. 0.11 events/exposure year) and lower rates of nocturnal confirmed hypoglycemia (5.5 vs. 9.3 events/exposure year), whereas rates of confirmed hypoglycemia were similar (58 vs. 55 events/exposure year) at 26 wk irrespective of continuation or not (data not shown).

Hyperglycemia with ketosis

The rate of hyperglycemic episodes (> 14 mmol/L) with ketosis (> 1.5 mmol/L) was significantly lower for IDEg vs. IDEt [0.7 vs. 1.1 events/exposure year, treatment ratio 0.41 (0.22; 0.78) 95% CI, p = 0.0066; Fig. 5], and lower rates were observed for IDEg compared to IDEt for all age groups. The same pattern was also observed in the ETS population. When stratified by age, children 1–5 yr of age had a higher rate of episodes of hyperglycemia with ketosis in both treatment groups (1.34 vs. 1.61 events/exposure year for IDEg vs. IDEt, respectively) compared with the two older age groups.
Table 4. Hypoglycemia

| Edeg (n = 174) | EDet (n = 175) |
|---------------|---------------|
| Event Rate (E/R per 100 PYE) |
| | n | % | E/R | n | % | E/R |
| All confirmed hypoglycemia | 171 | 98.3 | 9317 | 5771 | 168 | 96.0 | 7967 | 5405 |
| Nocturnal confirmed hypoglycemia | 133 | 76.4 | 973 | 603 | 125 | 71.4 | 1120 | 760 |
| All reported severe hypoglycemia | 31 | 17.8 | 49 | 51 | 24 | 13.7 | 48 | 33 |
| Externally confirmed severe episodes | 28 | 16.1 | 61 | 38 | 22 | 12.6 | 38 | 26 |
| Altered mental status and cannot assist in own care | 21 | 12.1 | 46 | 28 | 11 | 6.3 | 18 | 12 |
| Coma ± convulsions | 6 | 3.4 | 8 | 5 | 7 | 4.0 | 10 | 7 |
| Not severe hypoglycemia | 5 | 2.9 | 13 | 8 | 5 | 2.9 | 8 | 5 |
| Not possible to classify | 5 | 2.9 | 8 | 5 | 1 | 0.6 | 2 | 1 |

E, number of events; Edeg, insulin degludec; EDet, insulin detemir; n, number of participants; %, percentage of participants; R, event rate per 100 patient-years of exposure; SAS, safety analysis set.

Fig. 5. Rate of hyperglycemia with ketosis. Mean values with error bars (standard error of the mean) based on full analysis set and last observation carried forward imputed data. P-values are from an ANCOVA model. Edeg, insulin degludec; EDet, insulin detemir.

(0.50 vs. 0.92 events/exposure year for Edeg6–11 vs. EDet6–11, and 0.43 vs. 0.95 events/exposure year for Edeg12–17 vs. EDet12–17, respectively).

Other safety endpoints

At 52 wk, mean body weight SD scores had increased in the Edeg group but remained relatively unchanged in the EDet group [change: +0.11 vs. –0.06 kg, ETD: 0.17 (0.10; 0.25)95% CI, p < 0.0001].

AE profiles were similar for Edeg and EDet (Table 5). The majority of reported AEs for both groups were mild or moderate in severity and considered unlikely to be related to trial product. Of those considered possibly or probably related to trial product, ~97% were resolved by the end of the trial. The observed rates of serious AEs (SAEs) were also similar for Edeg and EDet (Table 5) and the most common SAEs were infections, hypoglycemia and hyperglycemia for both groups. The rate of SAEs considered possibly or probably related to the investigational medicinal product was five events per 100 PYE with Edeg and 3 events per 100 PYE with EDet, respectively. Only three participants, all from the EDet group, withdrew from the trial due to AEs (wrong trial drug administration, hypoglycemic seizure and anxiety disorder). Two cases of DKA were reported, both in the Edeg group, but were considered unlikely to be related to trial product.

The mean level of insulin antibodies cross-reacting between insulin analogs and human insulin decreased slightly with Edeg and increased slightly with EDet during the trial period (data not shown). No clinically relevant differences either from baseline to end of treatment or between the two treatment groups were observed for vital signs, physical examination, electrocardiograms, fundoscopy or laboratory measurements.

CGM subgroup analysis

In the subgroup of participants who performed CGM assessment before and during treatment with Edeg (74 participants) and EDet (75 participants) in the main trial period, the event rates for low IG and high IG generally reflected the pattern for hypo-
IDeg effective and safe in pediatric T1D

and hyperglycemic episodes. At wk 26, there were no significant differences between the IDeg and IDet groups for either IG < 3.1 mmol/L [IDeg:IDet ratio: 1.50 (0.97; 2.32)IDeg/IDet or IG < 3.9 mmol/L [IDeg:IDet ratio: 1.29 (0.98; 1.71)IDeg/IDet]. Nocturnally, observed rates with IDeg and IDet were 2.49 vs. 3.13 events per 100 PYE for IG < 3.1 mmol/L and 5.16 vs. 5.22 events per 100 PYE for IG < 3.9 mmol/L. Owing to the low number of nocturnal events, no statistical analysis was conducted. The duration of low IGs was not significantly different between IDeg and IDet for either IG < 3.1 mmol/L [IDeg–IDet contrast: 0.12 h (−0.33; 0.56)IDeg/IDet, NS] or IG < 3.9 mmol/L [IDeg–IDet contrast: 0.30 h (−0.37; 0.97)IDeg/IDet, NS].

The observed rate of high IGs after 26 wk was 11.20 (IDeg) vs. 10.66 (IDet) events per 100 PYE, respectively, with no significant difference between treatments [IDeg–IDet contrast: 1.03 (0.91; 1.17)IDeg/IDet, NS]. Nocturnal observed high IG rates after 26 wk were 12.05 (IDeg) vs. 10.61 (IDet) events per 100 PYE, respectively. There was no significant difference between treatments in the observed duration of high IGs overall [8.07 vs. 7.40 h; IDeg–IDet contrast: 0.47 (−0.69; 1.64)IDeg/IDet, NS] or nocturnally (2.92 vs. 2.12 h for IDeg vs. IDet, respectively).

Discussion

Intensive insulin therapy is associated with reduced long-term complications compared with non-intensive therapy in people with T1D and as such has become the standard of care. Treating intensively to reach glycemic targets can be particularly challenging in children, as their needs are in constant flux during their growth and development toward adulthood. Although a basal–bolus regimen containing basal insulin analogs enables many patients to achieve their glycemic targets, issues associated with variability of action, and an action profile requiring strict administration timing, can reduce the likelihood of attaining good glycemic control, particularly for children and adolescents, whose daily routine (and/or that of their parent/caregiver) can vary substantially. Poor glycemic control can result in persistent hyperglycemia and increasing risk of DKA. IDeg has a duration of action exceeding 42 h and a reduced intra-patient variability in glucose-lowering effect, and thus may offer a desirable alternative to other insulin analogs by enabling a degree of flexibility in dosing time when needed (17, 27).

This study has showed that IDeg OD provides effective long-term improvements in glycemic control, when compared with IDet OD or BID, both with mealtime IAsp in children with T1D as young as 1 yr of age. In this study, the titration guideline recommended that IDeg be dosed at the same time each day and IDet in accordance with local labeling. Throughout the trial, IDet doses were consistently higher than IDeg doses, showing that improvements in FPG were achieved with lower daily insulin doses in the IDeg group. On the basis of insulin dose ratios at 52 wk, the IDeg group required less basal insulin and less insulin overall compared with the IDet group. The higher IDet dose is probably in part due to 64% of the group receiving IDet BID, which is well-documented to increase basal doses (28, 29). The fact that IDeg ensures basal insulin coverage with one daily injection for all is an important benefit, particularly in children, as this reduces the burden of insulin injections.

Furthermore, although not formally tested in this study, flexibility in administration timing of IDeg was shown to be possible without compromising glycemic control in adults (20, 21). Owing to the preserved pharmacokinetic properties of IDeg across pediatric and adult populations (30), the potential for flexibility in dosing time when needed may make IDeg a very useful option for children and their caregivers.

In this trial, hypoglycemia was evaluated using both ISPAD classifications and a Novo Nordisk definition of confirmed hypoglycemic episodes PG < 3.1 mmol/L and/or severe hypoglycemia). Whereas severe hypoglycemia in adults is defined based on ability to self-treat (31), the ISPAD definition contains a broader, more subjective component: 'The child is having altered mental status and cannot assist in their care’ (10). On the basis of external classification, the majority of hypoglycemic episodes were deemed severe based on this most subjective component. For severe episodes ‘accompanied by either (semi) unconsciousness or coma ± convulsion’, post hoc analysis showed that the observed rates were either numerically lower with IDeg compared with IDet or similar between treatments, respectively. Thus, rates of severe hypoglycemia in this trial cannot be directly compared to rates of severe hypoglycemia in other pediatric trials where a narrower definition of severe hypoglycemia (e.g. episodes accompanied by seizure/floss of consciousness/coma) may have been used. Most severe episodes occurred during the day and in most cases, bolus insulin was the last insulin administered (results not shown). Moreover, incidence of severe hypoglycemia was low with <1% of hypoglycemic episodes classified as severe with either treatment using the ISPAD criteria.

Nocturnal hypoglycemia represents a pivotal parameter; as these episodes are usually independent of bolus doses, exercise or food intake, they provide the most relevant comparison standard for basal insulins. IDeg has consistently been showed to be associated with lower nocturnal hypoglycemia rates in adults compared with other basal insulins (19, 32–35). In this trial, there was a numerical reduction in nocturnal hypoglycemia in favor of IDeg, although statistical
significance was not achieved. The ultra-long, flat action profile and reduced intrapatient variability of IDeg facilitate improvements in FPG without increasing nocturnal hypoglycemic episodes. This property is especially beneficial for young children, where nocturnal hypoglycemia is of particular concern (36, 37). It should be noted that in this trial participants were transferred from pre-trial basal insulin to IDeg or IDet without specific dose reduction recommendations. However, evidence from the phase 3 trial program has led to the recommendation that the dose of both basal and bolus insulin should be reduced upon initiation of IDeg (38), and a similar recommendation would seem appropriate for children, based on the lower pre-breakfast, post-breakfast and post-dinner glucose levels observed in the IDeg arm in this trial. The values for pre- and post-breakfast in particular reflect the effect of greater basal control, which could be explained by the ultra-long duration of IDeg; a lower pre-breakfast, leading to a reduction in post-breakfast by default, although bolus insulin certainly will also play a role. The effect on post-lunch glucose values may be confounded by the availability (or lack of) medical assistance to administer bolus insulin during school/nursery hours.

At the opposite end of the glycemic spectrum, inadequate treatment can lead to hyperglycemia and if left untreated, rising ketone levels may progress to DKA, which is associated with increased morbidity and mortality (11). Prevention of DKA is of particular importance in children and adolescents, whose continuous cognitive and physical development place them at particular risk (11). In this trial, IDeg treatment led to a significant reduction in the rates of hyperglycemia with ketosis when compared with IDet. This reduction may be attributed to the ultra-long and flat pharmacokinetic profile of IDeg.

The CGM data from a subset of participants generally confirmed the patterns of hypo- and hyperglycemia (but not hyperglycemia with ketosis) discussed above, and showed that the duration of low IGs was not significantly longer for IDeg than IDet. In general, IDeg and IDet were both well tolerated and there were no clinically meaningful differences in relation to AEs, antibodies and standard safety parameters.

Limitations of this trial include the greater extent of discontinuation following the main study of participants in the IDet group compared with the IDeg group. Those participants from the IDet group who discontinued had a higher confirmed and severe hypoglycemia rate than those who continued. Secondly, this was an open-label trial and investigators may have been more vigilant in their management of the IDeg arm, including reporting of AEs. Furthermore, as 46% of those enrolled received IDet as part of their prior therapy, familiarity may have affected both the dosing and hypoglycemia rates observed, especially during the initial part of the trial.

The multinational nature of the trial population, covering 12 countries and a range of racial backgrounds, and the broad age range of participants who were all characteristic of patients with T1D, make these findings highly generalizable to the global pediatric population with T1D. Moreover, this study has provided a comprehensive assessment of severe hypoglycemia in a pediatric population.

Conclusion

In conclusion, this trial has showed that IDeg offers a valuable new addition to the treatment of T1D in children, with the potential to deliver similar glycemic control to IDet, achieved with comparable safety, but reduced hyperglycemia with ketosis in a single daily injection.

Acknowledgements

We thank the investigators, trial staff, and participants for their participation. We also thank Gemma Rogers PhD and Mark Nelson at Watermeadow Medical, funded by Novo Nordisk, for providing medical writing and editorial assistance. This study was funded by Novo Nordisk A/s; ClinicalTrials.gov number, NCT01513473.

Author contributions

N. T. acts as guarantor for the contents of this article. All authors (N. T., L. D., V. I., T. K., G. K., A. P., J. S., T. S., A. M. O. F., O. K. and T. D.) were involved in critical analysis and interpretation of the data, drafting/critically revising the article, and shared in the final responsibility for the content of the manuscript and the decision to submit it for publication.

Conflict of interest

N. T. has participated in advisory boards for Novo Nordisk, Eli Lilly and Lifescan. He has acted as a paid consultant to Novo Nordisk in the capacity of an external speaker at international meetings and his institution has received financial support for the delivery of clinical research trials from Novo Nordisk, Sanofi Aventis and Eli Lilly. L. D. has participated in advisory boards for Sanofi and received research support from Novo Nordisk. G. K. has acted as a consultant to Novo-Nordisk, providing consultation on the definition of hypoglycemia in children. A. P. has participated in advisory boards and speakers’ bureau for Novo Nordisk and has also received research support from Novo Nordisk. J. S. has received grant funding from Daiichi Sankyo. S. T. has participated
in advisory boards for Novo Nordisk, Sanofi Aventis, Eli Lilly and Lifescan. He has also received speaker honoraria from Roche Diagnostics, Novo Nordisk and Sanofi Aventis. A. M. O. F. and O. K. are employees of Novo Nordisk and own stock in the company. T. D. has received speakers’ honoraria, research support and has consulted for Eli Lilly, Medtronic, Novo Nordisk, Roche, Bristol-Myers Squibb (BMS)/AstraZeneca, Boehringer, Bayer, Abbott, DexCom and Sanofi. V. I. and T. K. have no conflicts of interest to disclose.

**Supporting Information**

Additional Supporting Information may be found in the online version of this article:

- Fig. S1. Trial design schematic.
- Table S1. Titration guideline for insulin dose at initiation.
- Table S2. Withdrawals according to prespecified criteria.

**References**

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 1993: 329: 979–986.
2. The Diabetes Control and Complications Trial Research Group. Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care 1995: 18: 1415–1427.
3. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000: 342: 381–389.
4. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002: 287: 2563–2569.
5. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005: 353: 2643–2653.
6. Halvorson M, Yasuda P, Carpenter S, Kaiserman K. Unique challenges for paediatric patients with diabetes. Diabetes Spectr 2005: 18: 167–173.
7. Rewers M, Pihoker C, Donaghe H, Hanas R, Swift P, Klingensmith GJ. ISPAD Clinical Practice Consensus Guidelines 2014 Compendium. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes 2014: 15 (Suppl. 20): 102–114.
8. Chiang JL, Kirkman MS, Laffel LM, Peters AL. Type 1 diabetes sourcebook authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 2014: 37: 2034–2054.
9. Desrocher M, Rovet J. Neurocognitive correlation of type 1 diabetes mellitus in childhood. Neuropsychol Dev 2004: 10: 36–52.
10. Clarke W, Jones T, Rewers A, Dunger D, Klingensmith GJ. Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediadtr Diabetes 2009: 10 (Suppl. 12): 134–145.
11. Wolsdorf J, ISPAD Clinical Practice Consensus Guidelines 2014 Compendium. Diabetic ketoacidosis in children and adolescents with diabetes. Pediatr Diabetes 2014: 15 (Suppl. 20): 154–179.
12. Morris AD, Boyle DI, McMahon AD, Greene SA, MacDonald TM, Newton RW. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. Diabetes Audit and Research in Tayside Scotland Medicines Monitoring Unit. Lancet 1997: 350: 1505–1510.
13. Rewers A, Chase HP, Mackenzie T et al. Predictors of acute complications in children with type 1 diabetes. JAMA 2002: 287: 2511–2518.
14. European Medicines Agency. Lantus® Summary of product characteristics (available from http://www.medicines.org.uk/emc/medicine/25506)
15. European Medicines Agency. Levemir® Summary of product characteristics (available from http://www.medicines.org.uk/emc/medicine/14584)
16. Heise T, Hovellman U, Nosek L, Botcher S, Granhall C, Hahner H. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetes 2011: 60 (Suppl. 1A): LB11 (Abstract).
17. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Hahner H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012: 14: 859–864.
18. Hahner H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet 2014: 53: 787–800.
19. Heller S, Buse J, Fisher M et al. Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal–bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal–Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012: 379: 1489–1497.
20. Meneghini L, Atkin SL, Gough SC et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily. A 26-week, randomised, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care 2013: 36: 858–864.
21. Mathieu C, Hollander P, Miranda-Palma B et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013: 98: 1154–1162.
22. World Medical Association Inc. Declaration of Helsinki. Ethical principles for medical research involving human subjects. J Indian Med Assoc 2009: 107: 403–405.

Pediatric Diabetes 2015: 16: 164–176
23. ICH Harmonised Tripartite Guideline. Guideline for good clinical practice. J Postgrad Med 2001: 47: 199–203.

24. LINDHOLM A, JENSEN LB, HOME PD, RASKIN P, BOEHM BO, RÅSTAM J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002: 25: 876–882.

25. MIRE-SLUIS AR, BARRETT YC, DEVARANARAYAN V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004: 289: 1–16.

26. Food and Drug Administration. Guidance for Industry: diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. Draft Guidance 2008 Rockville, MD: US Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) [online] (available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071624.pdf). Accessed February 21, 2012.

27. JONASSEN I, HAVELUND S, HØEG-JENSEN T, STEENSGAARD DB, WAHLUND PO, RIBEL U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012: 29: 2104–2114.

28. DEVRIES JH, NATTRASS M, PIEBER TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev 2007: 23: 441–454.

29. LE FLOCH JP, LÉVY M, MOSNIER-PUDAR H et al. Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT). Diabetes Care 2009: 32: 32–37.

30. BIESTER T, BLAESIG S, REMUS K et al. Insulin degludec’s ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes. Pediatr Diabetes 2014: 15: 27–33.

31. American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005: 28: 1245–1249.

32. GARBER AJ, KING AB, DEL PRATO S et al. Insulin degludec, an ultralong acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal–Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012: 379: 1498–1507.

33. BODE B, BUSE JB, FISHER M et al. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN Basal–Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med 2013: 30: 1293–1297.

34. DAVIES M, GROSS JL, ONO Y et al. Efficacy and safety of insulin degludec given as part of basal–bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes Obes Metab 2014: 16: 922–930.

35. DAVIS RE, MORRISSEY M, PETERS JR, WITTRUP-JENSEN K, KENNEDY-MARTIN T, CURRIE CJ. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin 2005: 21: 1477–1483.

36. FRIER BM. Hypoglycaemia and cognitive function in diabetes. Int J Clin Pract Suppl 2001: 123: 30–37.

37. SEAQUIST ER, ANDERSON J, CHILDS B et al. Hypoglycaemia and diabetes: a report of a workgroup of the American Diabetes Association and The Endocrine Society. J Clin Endocrinol Metab 2013: 98: 1845–1859.

38. European Medicines Agency. Tresiba® Summary of product characteristics (available from http://www.medicines.org.uk/emc/medicine/27363/SPC/Tresiba+200+units+mL+Pre-filled+Pen+(FlexTouch)/)